Day: February 7, 2023

ZeroBounce today announced the relaunch of its email validation and deliverability platform. ZeroBounce 2.0 will offer faster, more accurate email validation tools and increased security features on a seamless, intuitive platform.

ZeroBounce relaunches with 99% email validation accuracy

ZeroBounce relaunches with 99% email validation accuracy

SANTA BARBARA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) — ZeroBounce today announced the relaunch of its email validation and deliverability platform. ZeroBounce 2.0 will offer faster, more accurate email validation tools and increased security features on a seamless, intuitive platform.

ZeroBounce has increased the guaranteed accuracy of its email validation service from 98% to 99%. Furthermore, in light of data breaches and identity theft affecting millions, the platform elevated its security protocols to offer heightened data protection.

“After a year of tireless work, countless tests and a productive beta, we’ve got something ready that we know our customers will love,” says ZeroBounce CEO Liviu Tanase. “One of the biggest milestones was reaching 99% email validation accuracy, a benchmark in the industry. We’re grateful for our customers’ feedback and their contribution to all the improvements we’ve made.”

Ahead of the launch of the new platform, ZeroBounce has further expanded its security protocols. Aside from GDPR, the service is SOC 2 Type 2 compliant and ISO/IEC 270001 certified. Furthermore, ZeroBounce 2.0 now integrates with Okta identity protection services for even more security. “It was critical, with all of the upgrades, that we remained the safest, most protected email deliverability platform around. Whether it’s data security or the quality of our email verifier, we never settle,” said ZeroBounce COO Brian Minick.

ZeroBounce has migrated all data onto the new platform, including credits and subscriptions. Users don’t need to update their API configurations. With a brand-new, modern design, ZeroBounce 2.0 is available right away.

Recently, ZeroBounce has also launched an India website. The company offers its email validation service, email deliverability, blacklist monitoring and Activity Data tools on ZeroBounce.in, which processes data strictly in India.

About ZeroBounce

ZeroBounce is an award-winning email verification and deliverability platform helping 200,000+ customers land more emails in the inbox.

The service removes email typos, nonexistent and abuse email accounts, spam traps and other risky email addresses. ZeroBounce’s email deliverability toolkit further supports the safe inbox delivery of transactional and marketing emails. The company operates a military-grade security infrastructure.

ZeroBounce has validated more than 18 billion emails. Some of the companies it serves are Amazon, Disney, Netflix, LinkedIn, and Sephora.

In 2022, ZeroBounce founded Email Day (April 23), now an international holiday honoring email inventor Ray Tomlinson.

For more information, visit https://www.zerobounce.net/.

Contact Information:
Corina Leslie
PR Manager
support@zerobounce.net
+1-888-500-9521

Related Images

Image 1: ZeroBounce relaunches with 99% email validation accuracy

Screenshot of the ZeroBounce email validation platform on dark purple background, with ZeroBounce announcing its relaunch

This content was issued through the press release distribution service at Newswire.com.

Attachment

• ZeroBounce relaunches with 99% email validation accuracy

GlobeNewswire Distribution ID 8743739

Inaugural report details the emerging sustainability opportunities and challenges facing the global mobility industry on land, in the air, on the sea, and in space

SANTA MONICA, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) — UP.Partners, a mobility focused investment firm, released its inaugural Moving World Report: 2023 Macro and Micro Trends in Mobility. The 125 slide data-driven report draws evidence from dozens of interviews and hundreds of research studies to explore the multiplicity of important innovations and market dynamics impacting the movement of people and goods on the ground, in the air, at sea, and in space.

Some of the critical takeaways from the report include:

Investment: mobility funding has outpaced most tech sectors

• Mobility venture capital (VC) has seen a 30X increase in funding since 2013
• $130B allocated out of the Inflation Reduction Act (IRA) towards batteries & renewables, clean transportation, and hydrogen – likely to ignite significant innovation in the domestic US mobility ecosystem
• Europe’s proposed Green Deal Industrial Plan could dwarf the IRA’s investment in energy security and climate change ($369B) with over $1T allocated to making European continent net zero by 2050, leading with mobility
• Last mile and EVs have made up almost 50% of the dollars deployed since 2020 in mobility VC
• 12% of all VC over the last 10 years went to mobility
• Mobility tech stocks have exhibited more volatility than broader markets during the market correction in 2022, likely an artifact of the recent SPAC bubble

Environmental: mobility has become the most important climate segment

• Mobility represents 37% of U.S. CO2 emissions, the largest of any sector, with ground transportation representing 78% of that total, sea transportation at 11%, air transportation at 10%, and rail at just 1%
• 38% of climate tech/sustainability related investment dollars were made in mobility related companies

Batteries: shortages of battery raw materials will impact carmakers’ ability to meet EV targets — putting EV mandates in conflict with manufacturing reality

• Lithium price index went up almost 800% from 2020-2022
• Battery demand expected to increase by 900% by 2030
• The massive supply/demand dislocation for lithium, cobalt, and nickel is likely to increase the cost of EVs to consumers
• For the first time in 12 years, battery prices are going up per kWh, even though cell energy density is improving
• With current EV mandates, the U.S. is facing an existential national security energy risk by not establishing firm battery supply before pivoting market to 100% EVs
• U.S. electrical grid is not well prepared to take on the additional electric load of EVs at scale, at least in states that transitioned rapidly to renewable energy — if every car in California were electric today, electricity consumption would likely increase by 47%

Aviation: radical innovation is required to reverse aviation CO2 emissions trend

• Cargo drones flew 192% more drone delivery flights in 2022 compared to 2021
• 65,000 pilot shortage is expected by 2030 globally, a massive shortage that could cripple airlines and aircraft manufacturers, particularly regional airlines
• Sustainable Aviation Fuel (SAF) is the only near term rational pathway to making a real dent in aviation CO2 emissions in the next 10 – 15 years
• Over the long-term, hydrogen offers the most impactful potential strategy for decarbonizing aviation

Space: hypersonic travel and off-planet logistics are coming quickly

• SpaceX Starship will “change the game,” reducing the cost of getting a kilogram to orbit by orders of magnitude
• More than a dozen companies are pursuing hypersonic jets, with the war in Ukraine helping accelerate development of dual use technologies
• With NASA project Artemis, a permanent human presence on the Moon is just on the horizon

The insights in The Moving World Report may help startup founders, investors, regulators, corporations, and decision-makers successfully navigate these fundamental forces and better prepare for the likely futures of the moving world.

“Converging exponential technologies are disrupting aviation, EV adoption is accelerating at rapid pace, and electric 2- and 3-wheelers are displacing 1 million barrels of oil a day. Yet, the mobility sector has emerged as the largest CO2 contributor in the U.S. As many opportunities as there are in this rapidly transforming industry, there are even more challenges to be addressed,” said Cyrus Sigari, Co-Founder and Managing Partner of UP.Partners. “Transforming the moving world by moving people and goods cleaner, faster, safer, and at lower costs on the land, in the air, on the sea, and in space is a shared mission among governments, investors, and entrepreneurs alike. It is our hope that industry leaders and their teams will use the Moving World Report as a guide to confront the challenges and unlock the opportunities that lie ahead.”

About UP.Partners

UP.Partners is Transforming the Moving World by building and investing in companies that move people and goods cleaner, faster, safer, and at lower cost — on the ground, in the air, on the sea, and in space. The multi-strategy firm achieves this goal through its unique and virtuous ecosystem encompassing UP.Ventures, UP.Labs, and UP.Summit. UP.Ventures invests in companies and technologies to enable the future of mobility, working with some of the world’s most innovative investors and entrepreneurs. With flagship launch partner Porsche, UP.Labs is a first-of-its-kind venture lab, partnering with the world’s largest corporations to identify the most pressing challenges that they, and broader society, face. The UP.Summit is an invitation-only experience co-hosted with Tom and Steuart Walton and Ross Perot Jr., in Bentonville, AR and Dallas/Ft. Worth, TX respectively, bringing together the world’s most innovative minds to rethink the future of transportation. For more information, visit www.UP.partners or follow on Twitter @UpPartnersVC or LinkedIn.

Contact

Katie Duckhorn
katie@bulleitgroup.com

GlobeNewswire Distribution ID 8743774

Pivotal acquisition in Envision Pharma Group’s tech-enabled offerings provides clients with access to advanced AI to accelerate decision-making that optimizes their products’ path to market and ultimately supports the delivery of enhanced patient outcomes.

PHILADELPHIA, Feb. 07, 2023 (GLOBE NEWSWIRE) — Envision Pharma Group (Envision), a leading global technology-enabled commercialization, integrated medical capabilities and solutions, and data analytics partner to the life sciences industry, announced today it has acquired OKRA.ai, an award-winning technology company active in the provision of artificial intelligence (AI) solutions with present brains across commercialization, real-world evidence and data analytics, medical, and pricing for the pharmaceutical and life sciences industry.

OKRA.ai’s AI products and solutions translate large clinical, scientific, and commercial data sets into actionable insights to empower decision-making and drive action to clients in the life sciences industry.

“We are delighted to welcome OKRA.ai into the Envision Pharma Group family,” shares Meg Heim, CEO, Envision Pharma Group. “The acquisition of OKRA.ai marks an exciting milestone in Envision’s evolution as we continue to accelerate and deliver a compelling combination of technology-enabled capabilities and solutions to clients. The combination of Envision’s leading technology, capabilities, and solutions with OKRA.ai’s artificial intelligence solutions and expertise enables us to strengthen our offerings to clients across the product life cycle, but more importantly, support patients in their journey to health and wellness.”

Dr. Loubna Bouarfa, founder of OKRA.ai, will be joining Envision as a member of its Executive Leadership Team. Recently, Loubna won the prestigious Deloitte Fast 50 Women in Leadership Award and Forbes 50 Top Women in Tech. Loubna shares, “Today is a redefining moment for OKRA.ai. I am honored to be joining forces with Envision and see enormous opportunities for the growth of our combined expertise and solutions for clients in the life sciences industry. As part of Envision Pharma Group, we can accelerate our work to bring AI to the heart of decision-making across the life sciences industry. Our success will not only bring commercial benefit to clients but lead to improved patient outcomes across the globe.”

Based in the U.K. and Netherlands, OKRA.ai employs around 30 members of staff. The acquisition of OKRA.ai will bring the total number of Envision Pharma Group to 1,400+ employees across four continents.

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product lifecycle through a comprehensive suite of services and industry-leading technology solutions: including evidence-based scientific communications and engagement; commercialization and integrated medical consultancy; and HEOR/market access and data analytics capabilities. Learn more at www.envisionpharmagroup.com

About OKRA.ai 
OKRA.ai is a pioneer in developing AI solutions for the life sciences industry, bringing self-learning AI to optimize commercial, medical and market access decision making. Through its product portfolio, OKRA.ai delivers AI solutions to empower pharmaceutical companies with predictions and suggestions to bring novel treatments to patients in an efficient and effective way.

OKRA.ai was founded by Dr. Loubna Bouarfa in 2015 with a vision of moving the healthcare industry towards data-driven decision-making by explainable AI. Since then, OKRA.ai has been instrumental in building industry-first Explainable AI which empowers users by providing explanations behind predictions and suggestions. OKRA.ai currently consists of a highly qualified workforce across the UK and the Netherlands and has a nearly equal gender balance (48% of staff are female).

OKRA.ai’s solution suite compiles healthcare data from multiple sources, with coverage across hundreds of therapeutic areas, thousands of clinical trials and publications, millions of medically relevant free text and billions of data points that are specific to patient demographics. Since 2015, OKRA.ai has supported the commercialization of 92 molecules, 67 indications and 13 pharmaceutical brands.

Contact Information:
Colleen Carter
Communications
colleen.carter@envisionpharma.com
1 (203) 480 0080

This content was issued through the press release distribution service at Newswire.com.

GlobeNewswire Distribution ID 8743835

เตเมคูลา แคลิฟอร์เนีย, Feb. 07, 2023 (GLOBE NEWSWIRE) — กลุ่มบริษัท Nikkiso Clean Energy and Industrial Gases (“กลุ่มบริษัท”) ซึ่งเป็นส่วนหนึ่งของ Nikkiso จำกัด (ประเทศญี่ปุ่น) และดำเนินงานภายใต้บริษัท Cryogenic Industries จำกัด (สหรัฐอเมริกา) ได้เสร็จสิ้นการเข้าซื้อกิจการของ Cryotec Anlagenbau GmbH (Cryotec) ซึ่งตั้งอยู่ในเมืองวูร์เซิน รัฐแซกโซนี ประเทศเยอรมนีแล้ว ในจำนวนราคาที่ไม่เปิดเผย

Cryotec เป็นบริษัทด้านวิศวกรรมและการก่อสร้างโรงงานระดับโลก โดยให้บริการด้านการวางแผน การจัดการโครงการ การผลิต และบริการด้านวิศวกรรมของโรงงานแยกอากาศและการเปลี่ยนสถานะเป็นของเหลวที่ใช้ในลู่ลื่นไถล/ตู้คอนเทนเนอร์ และเทคโนโลยี CO2 ที่นำเสนอโซลูชันที่ปรับให้เหมาะกับลูกค้า

Cryotec จะดำเนินการโดยเป็นส่วนหนึ่งของโรงงาน GmbH ของกลุ่มบริษัท ซึ่งตั้งอยู่ใน Neuenburg am Rhine ประเทศเยอรมนี

กลุ่มประกอบด้วยหน่วยธุรกิจหกหน่วย: ปั๊มไครโอเจนิก ระบบแลกเปลี่ยนความร้อน ระบบกระบวนการ เชื้อเพลิงและโซลูชัน โครงสร้างพื้นฐานด้านพลังงาน และโครงการเชิงกลยุทธ์ และการบริการ Cryotec จะทำหน้าที่เป็นศูนย์ความสามารถและศูนย์การผลิตของกลุ่มบริษัท Nikkiso Clean Energy and Industrial Gases ในยุโรป

“Nikkiso จะส่งเสริมและขายโซลูชันบรรจุภัณฑ์อัจฉริยะจาก Cryotec ทั่วโลก ซึ่งจะช่วยลดและฟื้นฟูในด้านการปล่อยก๊าซคาร์บอนไดออกไซด์ และสนับสนุนเป้าหมายด้านความยั่งยืนของกลุ่มบริษัทต่อไป Cryotec จะสามารถเข้าถึงเทคโนโลยีนวัตกรรมที่พัฒนาขึ้นในแคลิฟอร์เนียและที่อื่น ๆ ในกลุ่มบริษัท Nikkiso ได้อย่างเต็มที่ และนำเสนอแพ็คเกจที่ปรับให้เหมาะสมกับพื้นที่ต่าง ๆ โซลูชัน และสถานีสำหรับ LH2 (Liquid Hydrogen หรือกระบวนการผลิตไฮโดรเจนเหลว) LNG (Liquefied Natural Gas หรือก๊าซธรรมชาติเหลว) แอมโมเนีย และแอปพลิเคชันการเก็บพลังงานด้วยความเย็นยิ่งยวดภายในเยอรมนีและยุโรป เราจะสนับสนุนการเติบโตของ Cryotec โดยการเพิ่มทรัพยากรและเพิ่มกิจกรรมการผลิตและการประกอบของเราในแซกโซนี และจัดหาโซลูชัน Cryotec ให้กับเยอรมนีและตลาดโลก” Peter Wagner ประธานเจ้าหน้าที่บริหารของ Cryogenic Industries และประธานของกลุ่มบริษัทกล่าว

Michael Kretschmer นายกรัฐมนตรีแห่งแซกโซนีกล่าวว่า: “การเข้าซื้อกิจการ Cryotec Anlagenbau โดย Nikkiso จะช่วยเสริมความแข็งแกร่งให้กับความเป็นสากลของบริษัทแซกซันแบบดั้งเดิมจากวูร์เซิน Nikkiso มีประสบการณ์ระดับโลกในด้านพลังงานหมุนเวียน ไฮโดรเจน และการจัดเก็บพลังงาน พลังงานหมุนเวียนและไฮโดรเจนสีเขียวมีบทบาทสำคัญในการบรรลุเป้าหมายด้านพลังงานและสภาพอากาศในแซกโซนี รัฐอิสระแซกโซนีนั้นเป็นสถานที่สำคัญสำหรับการวิจัยและการประยุกต์ใช้เทคโนโลยีไฮโดรเจนอยู่แล้ว ผมดีใจที่ Nikkiso จะมอบความเชี่ยวชาญให้กับแซกโซนีในอนาคต”

“Nikkiso จะสามารถช่วยเหลือในการทำให้โครงการนี้เป็นจริง ตลอดจนจัดหาและให้บริการสถานีเติมไฮโดรเจนเหลวและ LNG ในตลาดยุโรป” Ole Jensen รองประธานประจำยุโรปกล่าว “การซื้อกิจการครั้งนี้แสดงถึงความมุ่งมั่นของเราและสนับสนุนเป้าหมายของสหภาพยุโรปที่จะปล่อยคาร์บอนสุทธิให้เป็นศูนย์ (climate neutrality) ภายในปี 2593”

การเข้าซื้อกิจการจะมีผลในวันที่ 3 กุมภาพันธ์ 2566 เป็นต้นไป

เกี่ยวกับกลุ่มบริษัท Nikkiso Clean Energy & Industrial Gases 
กลุ่มบริษัท Nikkiso Clean Energy & Industrial Gases เป็นส่วนหนึ่งของแผนกอุตสาหกรรมของ Nikkiso จำกัด ประเทศญี่ปุ่น กลุ่มบริษัทดำเนินงานในสหรัฐอเมริกา ภายใต้บริษัท Cryogenic Industries จำกัด (ซึ่งเป็นสมาชิกของ Nikkiso จำกัด) บริษัทสมาชิกในกลุ่มผลิตและให้บริการอุปกรณ์เชิงวิศวกรรมสำหรับการแยกก๊าซด้วยความเย็นยิ่งยวด (เช่น ปั๊ม เทอร์โบเอกซ์เพนเดอร์ เครื่องแลกเปลี่ยนความร้อน เป็นต้น) และโรงแปรรูปสำหรับก๊าซอุตสาหกรรม (Industrial Gases), ก๊าซธรรมชาติเหลว (Natural Gas Liquefaction หรือ LNG), กระบวนการผลิตไฮโดรเจนเหลว (Hydrogen Liquefaction หรือ LH2) และวัฎจักรแร็งคินสารอินทรีย์เพื่อการนำความร้อนทิ้งกลับมาใช้ใหม่ (Organic Rankine Cycle for Waste Heat Recovery) บริษัท Cryogenic Industries ซึ่งได้ก่อตั้งขึ้นมากว่า 50 ปีนั้นเป็นบริษัทแม่ของบริษัท ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne และ Cryoquip พร้อมทั้งกิจการธุรกิจที่อยู่ภายใต้การดูแลควบคุมจำนวนประมาณ 20 กิจการ

สำหรับข้อมูลเพิ่มเติม กรุณาเยี่ยมชม www.NikkisoCEIG.com และ www.nikkiso.com

สำหรับการติดต่อด้านสื่อ:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

ดูรูปภาพประกอบประกาศนี้ได้ที่ https://www.globenewswire.com/NewsRoom/AttachmentNg/5818ee3c-2c93-4ad0-b03b-a87bda21cfce

GlobeNewswire Distribution ID 8744074

Carl D Francis takes the helm at medtech group focused on reversal of diabetes, NASH, and obesity

LONDON, Feb. 07, 2023 (GLOBE NEWSWIRE) — Today Keyron, the medical technology group focused on reversing type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity via an innovative medical device platform, announced the appointment of Carl D Francis as Chief Executive Officer.

“The continuing rise in obesity, diabetes, and all forms of fatty liver disease is one of the biggest health challenges the world faces today. Literally billions of people are affected, and the numbers continue to rise rapidly,” Francis said. “Keyron’s technology is a complete game-changer. An innovative, non-surgical, endoscopically-delivered, fully reversible treatment as an alternative to drastic bariatric surgeries is as exciting as it gets. I am really proud and honoured to be part of Keyron.”

The American Diabetes Association states that today 37m Americans suffer from diabetes, with 96m having pre-diabetes. The link between obesity and diabetes is well established, and according to The World Obesity Federation’s forecast in their recently released 2022 Atlas, 67% of women and 51% of men in the Americas will be living with obesity (BMI ≥ 30) by 2030.

Keyron’s patented technology is designed to be a fully endoscopic, outpatient procedure providing the same or greater metabolic benefits of gastric bypass surgery, including a reversal of type 2 diabetes and obesity, as well as NASH and liver fibrosis.

Following successful rodent studies in 2019 and swine studies in 2022, Keyron’s first-in-human trials are planned to begin in early 2024. Keyron is targeting to achieve FDA clearance by 2028, and a US launch is planned as the first target market. The company is now making plans to raise a $15m Series A funding round.

Dr Giorgio Castagneto Gissey, Keyron’s Chairman, said, “We are thrilled that Carl will be leading Keyron as we enter this critical stage of our development. Carl brings energy, focus, and senior leadership experience to ensure we realize our full potential. Keyron has always had high profile, world-leading board members and medical advisors, and we continue to bring onboard remarkable people. We are truly delighted to have been able to attract Carl.”

Francis was previously CEO of successful nano-technology group P2i. During his tenure the group grew from a handful of employees to global leadership in the functional nano-coating space. He was most recently CEO of UK-based medtech group Eyoto which specializes in advanced technologies in the optical and ophthalmic industries. He started his career as a US CPA, is a member of Mensa, and has a BSc from the University of Cincinnati.

CONTACT

For further information please contact:

• In the USA – Carl D Francis at c.francis@keyron.com or +1 (912) 429-3800
• In Europe – Dr Giorgio Castagneto Gissey at gcgissey@keyron.com or +44 7975 911101

ABOUT KEYRON

Keyron is a UK-based, preclinical-stage medical device and technology platform company aimed at a highly-effective treatment of metabolic diseases. Keyron’s patented ForePass is an innovative medical device designed to safely reverse type-2 diabetes, as well as NASH, and obesity. The company has already demonstrated a full reversal of insulin resistance in animal studies, and recently published the results in The Lancet EBioMedicine. Keyron has upcoming clinical trials in South America and aims to then carry out further clinical trials in the USA. Its founders, directors, advisors and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company is backed by multiple institutional investors based in the USA and EMEA.

GlobeNewswire Distribution ID 8743797

SOUTHAMPTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation (OTC Pink: ETCC) (“ETC” or the “Company”) announced that its Aircrew Training Systems business unit (“ATS”) was awarded an $85 million contract for the delivery of an Aeromedical Center including the building and all related facilities, in addition to the following products:

• Authentic tactical flight simulator (“ATFS-400 25”),
• GL – 1500 spatial disorientation trainer,
• Altitude chamber (12 person),
• Portable hyperbaric chamber,
• Ejection seat simulator,
• Night vision/night vision goggle training system, and
• A water survival system.

The services portion of this contract provides integrated logistics services, pilot physiology and personnel training services through ETC’s NASTAR Center and facility support services.

“This contract represents another significant milestone for ETC. We are pleased to have been chosen to supply our ATS customer with an Aeromedical Center with products and services designed to aid them in increasing their aviation training capabilities that protect pilots from the physiological dangers of flight,” states Robert Laurent, CEO and President.

About ETC:

ETC designs, manufactures, and sells software driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies. ETC’s unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC is headquartered in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements

This news release contains forward-looking statements, which are based on management’s expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include words such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “future”, “predict”, “potential”, “intend”, or “continue”, and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance. Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

GlobeNewswire Distribution ID 8743642